In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Dofetilide is under clinical development by Hyloris Pharmaceuticals and currently in Phase I for Atrial Flutter.

The new year has arrived, it’s a time for new beginnings, celebration, and reflection. However, the excitement of New Year’s festivities—and the overindulgence that often accompanies them—can lead to ...

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it.